UK markets closed

ABIVAX Société Anonyme (AAVXF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
32.000.00 (0.00%)
At close: 08:30AM EST
Full screen
Loading interactive chart…
  • EQS Group

    Abivax's phase 1/2 clinical study results of ABX196 in liver cancer to be presented on Jan. 21, at ASCO GI Cancers Symposium 2022

    DGAP-News: ABIVAX / Key word(s): Study results/Conference19.01.2022 / 08:00 The issuer is solely responsible for the content of this announcement.Abivax's phase 1/2 clinical study results of ABX196 in liver cancer to be presented on Jan. 21, at ASCO GI Cancers Symposium 2022 ABX196 phase 1/2 study results for the treatment of hepatocellular carcinoma (HCC) were selected for a presentation at the ASCO Gastrointestinal Cancers Symposium 2022 ABX196 at a maximum dose of 0.4µg was very well tolerate

  • EQS Group

    Abivax receives EMA Scientific Advice supportive of moving ABX464 into phase 3 clinical testing in ulcerative colitis

    DGAP-News: ABIVAX / Key word(s): Study13.01.2022 / 08:00 The issuer is solely responsible for the content of this announcement.Abivax receives EMA Scientific Advice supportive of moving ABX464 into phase 3 clinical testing in ulcerative colitis The responses from the European Medicines Agency (EMA) within the scientific advice meeting support moving 25mg and 50mg ABX464 into a phase 3 clinical program in ulcerative colitis (UC) Abivax to present at the virtual J.P. Morgan Healthcare Conference o

  • EQS Group

    Abivax to present at the J.P. Morgan 40th Annual Healthcare Conference

    DGAP-News: ABIVAX / Key word(s): Conference15.12.2021 / 18:30 The issuer is solely responsible for the content of this announcement.Abivax to present at the J.P. Morgan 40th Annual Healthcare Conference Abivax's presentation at the virtual J.P. Morgan Healthcare Conference scheduled for Thursday, January 13, 2022, at 12:00-12:40 pm ET (9:00-9:40 am PST and 6:00-6:40 pm CET) FDA end-of-phase-2 feedback received, raising no objections to proceeding ABX464 into pivotal phase 3 testing in ulcerative